Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.84 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.84 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.84 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22483752 | 0.94 | HDAC1 (0.76) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL13965309 | 0.91 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL1007344 | 0.85 | MAPT (0.62) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL20952239 | 0.85 | HDAC1 (0.91) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL13965297 | 0.82 | HDAC1 (0.71) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL1007825 | 0.82 | HDAC1 (0.57) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL8285512 | 0.82 | HDAC1 (0.71) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL13783993 | 0.81 | HDAC1 (0.93) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL13965291 | 0.81 | HDAC1 (0.69) | HDAC1HDAC2HDAC8HDAC3NCOR2 | |
| SCHEMBL5807174 | 0.80 | HDAC1 (1.00) | HDAC1HDAC2HDAC8HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2005053610-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | AADAC, BRDT, HDAC5 | HDAC1 5/4885HDAC2 7/4885HDAC8 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.